Head to Head Comparison: Tempus AI (NASDAQ:TEM) & Enovis (NYSE:ENOV)

Tempus AI (NASDAQ:TEM) and Enovis (NYSE:ENOV) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Tempus AI and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempus AI	-19.27%	-53.30%	-11.28%
Enovis	-52.69%	8.74%	4.19%

Valuation and Earnings

This table compares Tempus AI and Enovis”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$1.27 billion	7.65	-$245.03 million	($1.41)	-38.60
Enovis	$2.25 billion	0.64	-$1.18 billion	($20.71)	-1.22

Tempus AI has higher earnings, but lower revenue than Enovis. Tempus AI is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

24.2% of Tempus AI shares are held by institutional investors. Comparatively, 98.5% of Enovis shares are held by institutional investors. 26.3% of Tempus AI shares are held by insiders. Comparatively, 2.7% of Enovis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Tempus AI and Enovis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	2	3	9	0	2.50
Enovis	1	0	6	2	3.00

Tempus AI presently has a consensus target price of $71.36, indicating a potential upside of 31.12%. Enovis has a consensus target price of $47.43, indicating a potential upside of 88.31%. Given Enovis’ stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Tempus AI.

Risk & Volatility

Tempus AI has a beta of 4.9, meaning that its stock price is 390% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500.

Summary

Enovis beats Tempus AI on 8 of the 15 factors compared between the two stocks.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.